Human leukocyte immunoglobulin (Ig)-like receptors (LILR)
Human leukocyte immunoglobulin (Ig)-like receptors; LILR; Immunoglobulin-like transcript; ILT; LIR; MIR; CD85
Human Leukocyte Immunoglobulin (Ig)-like Receptors (LILR) constitute a family of 11 innate immune-modulatory receptors that are primarily expressed on lymphoid and myeloid cells. Structurally and functionally, they resemble Killer Cell Ig-like Receptors (KIR) expressed on Natural Killer (NK) cells and subsets of T lymphocytes.
LILR are classified into activating (LILRA) and inhibitory (LILRB) types based on the differences in their associated signaling transduction domains (D). The activating LILRA subtypes include LILRA1–A6, which are also known as LIR6, ILT1, ILT6, ILT7, ILT11, and ILT8, respectively. The inhibitory LILRB subtypes include LILRB1–B5, which are also known as ILT2, ILT4, ILT5, ILT3, and LIR8, respectively. Except for soluble LILRA3, LILRA primarily mediates immune activation, while LILRB1-5 mainly inhibit immune responses and mediate immune tolerance. LILRB can serve as immune checkpoint molecules.
Abnormal expression and function of LILR are associated with various pathological conditions, including immunodeficiency (infections and malignancies) and excessive immune responses (autoimmunity and allograft rejection)[1][2][3].
LILR are classified into activating (LILRA) and inhibitory (LILRB) types based on the differences in their associated signaling transduction domains (D). The activating LILRA subtypes include LILRA1–A6, which are also known as LIR6, ILT1, ILT6, ILT7, ILT11, and ILT8, respectively. The inhibitory LILRB subtypes include LILRB1–B5, which are also known as ILT2, ILT4, ILT5, ILT3, and LIR8, respectively. Except for soluble LILRA3, LILRA primarily mediates immune activation, while LILRB1-5 mainly inhibit immune responses and mediate immune tolerance. LILRB can serve as immune checkpoint molecules.
Abnormal expression and function of LILR are associated with various pathological conditions, including immunodeficiency (infections and malignancies) and excessive immune responses (autoimmunity and allograft rejection)[1][2][3].
Human leukocyte immunoglobulin (Ig)-like receptors (LILR) Isoform Specific Products
All Product Categories
-
Human leukocyte immunoglobulin (Ig)-like receptors (LILR) Related Products (7)
Related Products (7)
-
Human leukocyte immunoglobulin (Ig)-like receptors (LILR) Isoform Comparison
-
Daxdilimab
0 ImagesCat. No.: HY-P99226CAS No.: 2245966-28-1Synonyms: MEDI7734; VIB7734Daxdilimab is an anti-ILT7 monoclonal antibody, ILT7 is a cell surface molecule specific to the pDC type of dendritic cells. Daxdilimab can be used in acute lung injury (ALI) in patients with COVID-19 infection research.
-
Zamristobart
0 ImagesCat. No.: HY-P991727CAS No.: 3036192-53-4Synonyms: SAR-444881; BND-22
-
Daxdilimab (FUT8-KO)
0 ImagesCat. No.: HY-P99226ADaxdilimab (FUT8-KO) is an anti-ILT7 monoclonal antibody expressed by CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose deficiency enhances the antibody-dependent cellular cytotoxicity (ADCC) effect of the antibody.
-
IB15C
0 ImagesCat. No.: HY-184157IB15C is an ILT3 (LILRB4) inhibitor with a human Kd of 0.92 μM. IB15C binds to a specific ILT3 pocket, disrupts ApoE interaction, and interferes with downstream inhibitory signaling pathways. IB15C reduces SHP1 and SHP2 phosphorylation, suppresses pro-inflammatory cytokine secretion, enhances amyloid uptake, and attenuates NF-κB activation. IB15C can be used for the research of alzheimer's disease.
-
Anti-OSCAR Antibody
0 ImagesCat. No.: HY-P992285
-
4-Methylphthalic anhydride
0 ImagesCat. No.: HY-W015405CAS No.: 19438-61-04-Methylphthalic anhydride is an organic acid anhydride and an immunogen/sensitizer. 4-Methylphthalic anhydride induces the production of specific immunoglobulin E and immunoglobulin G antibodies. 4-Methylphthalic anhydride is used in studies of occupational allergy.
-
Ricefidase
0 ImagesCat. No.: HY-P992154Synonyms: KJ-103Ricefidase (KJ-103) is a recombinant human immunoglobulin G-degrading enzyme. Ricefidase efficiently cleaves human IgG at the hinge region. Ricefidase rapidly reduces IgG levels. Ricefidase has low immunogenicity and clears AAV neutralizing antibodies. Ricefidase is applicable to research related to desensitization of all IgG subclasses and improvement of the suitability of AAV-based gene therapy.
